This trial, conducted in Canada and the USA, assessed the effect of Hydroxychloroquine as a post exposure prophylaxis or a treatment for patients with mild COVID-19 infections.
- Test if hydroxychloroquine can prevent development of COVID-19 disease after known exposure to the SARS-CoV2 virus.
- Test if early preemptive therapy in non-hospitalized adults with symptomatic COVID-19 disease can prevent disease progression and hospitalization
Type of study: Interventional, RCT, Phase 3
Treatment tested: Hydroxychloroquine
Countries: Canada, USA
Sample size: 3000
- Adult Household contacts or Healthcare workers exposed to persons with COVID-19 disease within 4 days, or
- Non-hospitalized adults with symptomatic COVID-19 disease within 4 days of onset
Study status: Completed
- David Boulware, MD, MPH, University of Minnesota
- Study ID: NCT04308668
- Trial registry
- Study website
- The New England Journal of Medicine, August 2020
- Annals of Internal Medicine, June 2020
- Canadian Journal of Anesthesia/Journal canadien d’anesthésie, May 2020
Last modified: September 2020
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.